SFX by Ex Libris Inc.

Title:	Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease
Source:	Human Molecular Genetics [0964-6906] Björkqvist, Maria yr:2006

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Johnson, Michael A A. "Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease." Journal of neurochemistry 97.3 (2006): 737-46.
description	2.	Van Raamsdonk, J. M., Gibson, W. T., Pearson, J.,, Zoe M. "Body weight is modulated by levels of full-length Huntingtin." Human molecular genetics 15.9: 1513-1523.
description	3.	Van Raamsdonk, J. "Testicular degeneration in Huntington disease." Neurobiology of disease 26.3 (2007): 512-520.
description	4.	Li, J. "The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies." NeuroRx 2.3 (2005): 447-464.
description	5.	Sciruicchio, V. "Topographic classification of EEG patterns in Huntington's disease." Neurology & clinical neurophysiology 2004 (2004): 37-37.
description	6.	Poewe, K. "Diffusion-weighted imaging in Huntington's disease." Movement disorders 21.7 (2006): 1043-7.
description	7.	Menalled, Liliana B B. "Mouse models of Huntington's disease." Trends in Pharmacological Sciences 23.1 (2001): 32-9.
description	8.	Hoffner, G. "Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers." Journal of neurochemistry 95.1 (2005): 125-36.
description	9.	Caboche, J. "Role of dopamine in Huntington's disease." Médecine sciences 22.2 (2006): 115-117.
description	10.	Chang, D. "Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons." Neurobiology of disease 22.2: 388-400.
description	11.	Cattaneo, E. "Mutant huntingtin goes straight to the heart." Nature neuroscience 5.8: 711-712.
description	12.	Gomez, Eileen M T. "Brain-specific factors in combination with mutant huntingtin induce gene-specific transcriptional dysregulation." Molecular and cellular neurosciences 31.4 (2006): 661-675.
description	13.	Lang, Anthony E E. "The progression of Parkinson disease: a hypothesis." Neurology 68.12 (2007): 948-52.
description	14.	Mangiarini, L. "Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice." Cell 87.3 (1996): 493-506.
description	15.	Yang, Cheryl L L. "Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease." The journal of neuroscience 22.18 (2002): 7862-72.
description	16.	Li, Shi-Hua H. "Huntingtin–protein interactions and the pathogenesis of Huntington's disease." Trends in genetics 20.3 (2004): 146-154.
description	17.	Markianos, M. "Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington's disease." Neuro endocrinology letters 28.2 (2007): 199-203.
description	18.	Baumann, Christian R R. "Hypocretin-1 (orexin A) levels are normal in Huntington's disease." Journal of neurology 253.9 (2006): 1232-3.
description	19.	Donner, Elizabeth J J. "Electroencephalographic correlate of juvenile Huntington's disease." Journal of child neurology 19.7 (2004): 541-3.
description	20.	Stack, E. "Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice." Biochimica et biophysica acta 1762.Mar (2006): 373-80.